CG
OKUR

Carlyle Group’s OnKure Therapeutics OKUR Stock Holding History

Carlyle Group’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Hold
269,895
– – 0.01% 13
2025
Q4 		$772K Hold
269,895
– – 0.01% 14
2025
Q3 		$742K Hold
269,895
– – 0.02% 15
2025
Q2 		$642K Hold
269,895
– – 0.01% 18
2025
Q1 		$1.16M Hold
269,895
– – 0.03% 19
2024
Q4 		$2.33M Sell
269,895
-1
-0% -$15 0.06% 19
2024
Q3 		$4.53M Hold
269,896
– – 0.48% 12
2024
Q2 		$4.16M Hold
269,896
– – 0.39% 15
2024
Q1 		$4.45M Hold
269,896
– – 0.28% 17
2023
Q4 		$4.32M Hold
269,896
– – 0.21% 16
2023
Q3 		$20.5M Hold
269,896
– – 0.89% 11
2023
Q2 		$17.7M Buy
269,896
+62,500
+30% +$5.04M 0.63% 11
2023
Q1 		$12.2M Buy
+207,396
New +$7.52M 0.37% 14

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Carlyle Group's OKUR Position: Q1 2026 in Review

Carlyle Group held its OnKure Therapeutics (OKUR) position steady in Q1 2026 at 269,895 shares worth $1.12M. The position accounts for 0.01% of the portfolio, ranked #13.

Carlyle Group first reported a position in OKUR in Q1 2023 and has held it in 13 quarters since. The position peaked at $20.5M in Q3 2023. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Carlyle Group held 269,895 shares of OnKure Therapeutics worth $1.12M as of Q1 2026.
  • Carlyle Group left its OnKure Therapeutics share count unchanged in Q1 2026.
  • OnKure Therapeutics made up 0.01% of Carlyle Group's portfolio in Q1 2026, its #13 holding.
  • Carlyle Group first reported a position in OnKure Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Carlyle Group's OnKure Therapeutics position peaked at $20.5M in Q3 2023.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Carlyle Group's 13F filing for Q1 2026, filed 8 May 2026.